Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the program expands to Medicare Part B and smaller biotechs.
Immuno-Oncology Stars Keytruda, Opdivo Likely To Come Into IRA Crosshairs